Cargando…
The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response
Escape mutations in the spike protein of SARS-CoV-2 are a major reason for Omicron breakthrough infections. After basal vaccination only very low titers of Omicron neutralizing antibodies are present. However, booster vaccinations induce higher titers against the Omicron variant. The neutralization...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319856/ https://www.ncbi.nlm.nih.gov/pubmed/37402816 http://dx.doi.org/10.1038/s41598-023-38077-x |
_version_ | 1785068328328364032 |
---|---|
author | Hein, Sascha Sabino, Catarina Benz, Nuka Ivalu Görgülü, Esra Maier, Thorsten Jürgen Oberle, Doris Hildt, Eberhard |
author_facet | Hein, Sascha Sabino, Catarina Benz, Nuka Ivalu Görgülü, Esra Maier, Thorsten Jürgen Oberle, Doris Hildt, Eberhard |
author_sort | Hein, Sascha |
collection | PubMed |
description | Escape mutations in the spike protein of SARS-CoV-2 are a major reason for Omicron breakthrough infections. After basal vaccination only very low titers of Omicron neutralizing antibodies are present. However, booster vaccinations induce higher titers against the Omicron variant. The neutralization of the Delta and Omicron variants by sera obtained 6 months after 3rd vaccination and 2 weeks or 6 months after 4th vaccination with a monovalent RNA vaccine (Spikevax) was analyzed. It was observed for the Omicron variant that 6 months after the fourth vaccination, the titer returns to the same very low neutralizing capacity as 6 months after the third vaccination. The Delta variant neutralizing capacity wanes with a comparable kinetic although the titers are higher as compared to the Omicron variant. This indicates that the fourth vaccination with a monovalent vaccine based on the ancestral isolate neither affects the kinetic of the waning nor the breadth of the humoral response. |
format | Online Article Text |
id | pubmed-10319856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-103198562023-07-06 The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response Hein, Sascha Sabino, Catarina Benz, Nuka Ivalu Görgülü, Esra Maier, Thorsten Jürgen Oberle, Doris Hildt, Eberhard Sci Rep Article Escape mutations in the spike protein of SARS-CoV-2 are a major reason for Omicron breakthrough infections. After basal vaccination only very low titers of Omicron neutralizing antibodies are present. However, booster vaccinations induce higher titers against the Omicron variant. The neutralization of the Delta and Omicron variants by sera obtained 6 months after 3rd vaccination and 2 weeks or 6 months after 4th vaccination with a monovalent RNA vaccine (Spikevax) was analyzed. It was observed for the Omicron variant that 6 months after the fourth vaccination, the titer returns to the same very low neutralizing capacity as 6 months after the third vaccination. The Delta variant neutralizing capacity wanes with a comparable kinetic although the titers are higher as compared to the Omicron variant. This indicates that the fourth vaccination with a monovalent vaccine based on the ancestral isolate neither affects the kinetic of the waning nor the breadth of the humoral response. Nature Publishing Group UK 2023-07-04 /pmc/articles/PMC10319856/ /pubmed/37402816 http://dx.doi.org/10.1038/s41598-023-38077-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hein, Sascha Sabino, Catarina Benz, Nuka Ivalu Görgülü, Esra Maier, Thorsten Jürgen Oberle, Doris Hildt, Eberhard The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
title | The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
title_full | The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
title_fullStr | The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
title_full_unstemmed | The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
title_short | The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
title_sort | fourth vaccination with a non-sars-cov-2 variant adapted vaccine fails to increase the breadth of the humoral immune response |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319856/ https://www.ncbi.nlm.nih.gov/pubmed/37402816 http://dx.doi.org/10.1038/s41598-023-38077-x |
work_keys_str_mv | AT heinsascha thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT sabinocatarina thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT benznukaivalu thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT gorguluesra thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT maierthorstenjurgen thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT oberledoris thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT hildteberhard thefourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT heinsascha fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT sabinocatarina fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT benznukaivalu fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT gorguluesra fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT maierthorstenjurgen fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT oberledoris fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse AT hildteberhard fourthvaccinationwithanonsarscov2variantadaptedvaccinefailstoincreasethebreadthofthehumoralimmuneresponse |